Relapsed/Refractory Solid tumors | Norton Healthcare

Indication: Relapsed/Refractory Solid tumors

A Phase 1 Open-Label Study Of The Safety, Tolerability And Preliminary Clinical Activity Of Allogeneic Invariant Natural Killer (INKT) Non-Transduced Cells (AGENT-797) As A Single Agent And In Combination With Approved Immune Checkpoint Inhibitors In Patients With Relapsed/Refractory Solid Tumors

Sub-indication: Miscellaneous Malignancies

Study Type: Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Agentus Therapeutics

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.